SCIENCE@home

Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase*

U. Laufs,J. Liao

Published 1998 in Journal of Biological Chemistry

ABSTRACT

The mechanism by which 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors increase endothelial nitric oxide synthase (eNOS) expression is unknown. To determine whether changes in isoprenoid synthesis affects eNOS expression, human endothelial cells were treated with the HMG-CoA reductase inhibitor, mevastatin (1–10 μm), in the presence ofl-mevalonate (200 μm), geranylgeranylpyrophosphate (GGPP, 1–10 μm), farnesylpyrophosphate (FPP, 5–10 μm), or low density lipoprotein (LDL, 1 mg/ml). Mevastatin increased eNOS mRNA and protein levels by 305 ± 15% and 180 ± 11%, respectively. Co-treatment with l-mevalonate or GGPP, but not FPP or LDL, reversed mevastatin’s effects. Because Rho GTPases undergo geranylgeranyl modification, we investigated whether Rho regulates eNOS expression. Immunoblot analyses and [35S]GTPγS-binding assays revealed that mevastatin inhibited Rho membrane translocation and GTP binding activity by 60 ± 5% and 78 ± 6%, both of which were reversed by co-treatment with GGPP but not FPP. Furthermore, inhibition of Rho by Clostridium botulinum C3 transferase (50 μg/ml) or by overexpression of a dominant-negative N19RhoA mutant increased eNOS expression. In contrast, activation of Rho byEscherichia coli cytotoxic necrotizing factor-1 (200 ng/ml) decreased eNOS expression. These findings indicate that Rho negatively regulates eNOS expression and that HMG-CoA reductase inhibitors up-regulate eNOS expression by blocking Rho geranylgeranylation, which is necessary for its membrane-associated activity.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-38 of 38 references · Page 1 of 1

CITED BY

Showing 1-100 of 1167 citing papers · Page 1 of 12

123412
Next